Centipedegrass extract induces apoptosis through the activation of caspases and the downregulation of PI3K/AKT and MAPK phosphorylation in leukemia cells

HYOUNG-WOO BAI1*, SRILATHA BADABOINA1*, CHUL-HONG PARK1,2, BO YUN CHOI1, YUN HEE NA1,3 and BYUNG YEOUP CHUNG1

1Advanced Radiation Technology Institute (ARTI), Korea Atomic Energy Research Institute (KAERI), Jeongeup-si, Jeollabuk-do 580-185; 2School of Biological Sciences and Biotechnology and 3Department of Molecular Medicine, Chonnam National University, Gwangju 500-757, Republic of Korea

Received May 30, 2014; Accepted November 17, 2014

DOI: 10.3892/ijmm.2014.2012

Abstract. Acute lymphoblastic leukemia (ALL), which involves the blood and bone marrow, is the most common type of cancer in children younger than 5 years of age. Previous studies have investigated the effects of centipedegrass extract (CGE), which is mainly composed of maysin and its derivatives, and have demonstrated that it has various biological activities, including antioxidant and anti-inflammatory activities, pancreatic lipase inhibitory activity, anti-adipogenic activity and insecticidal activity. To the best of our knowledge, this study is the first to investigate the anticancer effects of CGE in ALL cell lines and to elucidate the mechanisms underlying these effects. Cell viability was measured by thiazolyl blue tetrazolium blue (MTT) assay. Apoptosis, cell cycle progression and mitochondrial membrane potential (ΔΨm) were determined by flow cytometry. The effects of CGE on the phosphatidylinositol 3-kinase (PI3K)/AKT pathway and mitogen-activated protein kinases (MAPKs) were assessed by immunoblotting. PI3K, MAPK and caspase inhibitors were used to further confirm the molecular mechanisms involved. Our results clearly demonstrated that the proliferation of the ALL cells was significantly inhibited by CGE in a dose-dependent manner. Apoptosis was accompanied by the induction of significant G1 cell cycle arrest. The resulting alteration of the ∆Ψm increased the activity of caspase-3/7. The induction of apoptosis was enhanced by the combined treatment of CGE with a PI3K inhibitor or an extracellular signal-regulated kinase (ERK) inhibitor, whereas the CGE-induced apoptosis was inhibited in the presence of caspase inhibitors, such as Z-VAD-FMK and Z-IETD-FMK. Furthermore, CGE inhibited PI3K activity by decreasing the levels of phosphorylated (p-)AKT, p-BAD, and Bcl-2 together with the levels of MAPKs, including p-ERK and p-JNK, but demonstrated no effects on p38 MAPK. Thus, our data suggest that CGE may be a novel natural compound with potential for use as an antitumor agent in ALL.

Introduction

In recent years, flavonoids have been investigated intensively for the treatment of various types of cancer and have been proven to be potent anticancer agents (1,2). The therapeutic efficacy of many natural plants has already been described by practitioners of traditional medicine for several disorders. Centipedegrass [Eremochloa ophiuroides ( Munro) Hack], which is native to China and Southeast Asia, is one of the most versatile medicinal herbs (3). Composition analysis by liquid chromatography-mass spectrometry (LC-MS)/MS has helped to identify several C-glycosidic flavones and phenolic constituents from centipedegrass, including maysin and its derivatives. Centipedegrass extract (CGE), used in the present study, is mainly composed of orientin, isoorientin, rhamnosylisoorientin, derhamnosyl-maysin, maysin, luteolin and luteolin-6-C-bovinopyranose at the concentrations of 1.4, 28.1, 63.1, 49.1, 97.3, 34 and 85 µg/mg DW, respectively. Maysin and its derivatives have thus far been found only in centipedegrass, maize silk and teosinte. Centipedegrass is known to possess a wide spectrum of antibacterial, antifungal and insecticidal properties (4,5), and a recent study reported that CGE exhibits anti-adipogenic activity (6). However, the anticancer effects of flavonoid-rich centipedegrass against acute lymphoblastic leukemia (ALL) are not yet known.

ALL, which involves the blood and bone marrow, is the most common type of cancer in children younger than 5 years of age (7). ALL is composed of many subtypes that represent different clinical behaviors and require different therapy schemes (8,9). Family history and exposure to radiation may

Correspondence to: Dr Byung Yeoup Chung, Advanced Radiation Technology Institute (ARTI), Korea Atomic Energy Research Institute (KAERI), 29 Geumgu-gil, Jeongeup-si, Jeollabuk-do 580-185, Republic of Korea
E-mail: bychung@kaeri.re.kr

*Contributed equally

Key words: centipedegrass extract, apoptosis, acute lymphoblastic leukemia, Jurkat, CEM-CM3 cells, phosphatidylinositol 3-kinase/AKT, mitogen-activated protein kinase, caspase
affect the risk of developing ALL (10). Treatment includes chemotherapy, steroids, radiation therapy, intensive combined treatments (including bone marrow or stem cell transplants) and growth factors. The cost for the complete treatment of a child with ALL is approximately US $100,000 per patient (11). Therefore, the development of an effective chemotherapeutic regimen that selectively induces apoptosis in cancer cells is of great importance. Signaling pathways, such as the phosphatidylinositol 3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways are frequently upregulated in ALL (12-14).

To maintain tissue homeostasis in multicellular organisms, cell proliferation and cell death must be regulated. This regulation may be achieved, in part, by coupling the process of cell cycle progression and apoptosis (15). Apoptosis is a highly regulated process and some of its important characteristics are DNA fragmentation, cell shrinkage, nuclear condensation, phosphatidylserine (PS) flipping from the inner to the outer leaflet of the plasma membrane and the alteration of mitochondrial membrane potential (ΔΨm) (16-19). The timing and order of cell cycle events are monitored during cell cycle checkpoints that occur at the G1/S boundary, in the S phase and during the G2/M phase (20).

The current study was designed to demonstrate the effects of CGE on human leukemia cell lines. To the best of our knowledge, our data provide the first evidence that CGE functions as a broad-range anticancer agent by effectively triggering apoptosis in human leukemia cells through a mechanism involving the regulation of PI3K/AKT and MAPKs, which in turn leads to caspase activation and apoptosis.

Materials and methods

Preparation of the CGE. The preparation of CGE was carried out as previously described (21). The dried centipedegrass (5 kg) leaves were ground in a Wiley mill and passed through a 420-µm sieve. The ground sample (1 kg) was extracted 3 times with 80% methanol (MeOH, 100 l; Merck & Co, Inc., Whitehouse Station, NJ, USA) for 24 h with constant shaking at ambient temperature in the dark. The extracts were filtered using No. 2 filter paper (Advantec Mfs Inc., Dublin, CA, USA) and concentrated in vacuo (Advantec Mfs Inc., Tokyo, Japan) column and concentrated in vacuo. The MeOH extracts were fractionated with n-hexane and ethyl acetate (EA) (Merck & Co, Inc.). The EA extracts were concentrated in vacuo and the dried compounds were dissolved in MeOH. The dissolved extracts in MeOH were diluted in 20% MeOH and chromatographed over a Toyopearl HW-40C resin (Tosoh Co., Tokyo, Japan) column using 70% MeOH (elution volume, 700 ml). The fraction was evaporated and freeze dried. The dried extracts were reconstituted in dimethylsulfoxide (DMSO) for the treatment of the cells.

Reagents and antibodies. Unless otherwise specified, all chemicals were purchased from Sigma Chemical Co. (St. Louis, MO, USA), including thiazoyl blue tetrazolium blue (MTT), Annexin V-FITC, protease inhibitor cocktail, propidium iodide (PI) and DMSO. Antibodies to Bcl-2 (no. 5023), Bid (no. 2002), cytochrome c (no. 4247), poly(ADP-ribose) polymerase (PARP; no. 9542), caspase-3 (no. 9662), caspase-7 (no. 9492), caspase-9 (no. 9502), p-PI3K (no. 4228), p-AKT (Ser 473; no. 4058), p-AKT (Thr 308; no. 9275), AKT (no. 4691), p-BAD (Ser 136; no. 9291), HSP-60 (no. 4870) and GAPDH (no. 2118), as well as a horseradish peroxidase (HRP)-conjugated secondary antibody (no. 7074), the PI3K inhibitor, LY294002, and the ERK inhibitor, U0126, were obtained from Cell Signaling Technology (Beverly, MA, USA). Pan-caspase inhibitors (Z-IE TD-FMK and Z-VA D-FMK) were purchased from R&D Systems (Minneapolis, MN, USA). The ECL plus chemiluminescence kit was obtained from Amersham Pharmacia Biotech (Piscataway, NJ, USA). The mitochondrial dye, 3,3'-diethyloxarocarbocyanine iodide [DiOC(3)], was obtained from Molecular Probes (Carlsbad, CA, USA).

Cell culture and viability assay. The Jurkat (TIB-152), CEM-CM3 (TIB-195), CCRF-CEM (CCL-119) and MOLT-4 (CRL-1582) cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in RPMI-1640 medium supplemented with 10% heat-inactivated FBS and 100 µl penicillin at 37°C in a humidified 5% CO₂ incubator.

MTT was used to evaluate the viability of the cells. Briefly, the leukemia cells were plated at a density 1x10⁵ cells/well in 96-well plates. The cells were treated with a series of concentrations (2.5, 5, 10, 20, 40, 80 and 160 µg/ml) of CGE. CGE was dissolved in DMSO and the final concentration of DMSO in the culture medium was <0.05%. After 24 h of incubation with CGE, 10 µl of MTT solution (5 mg/ml in PBS as a stock solution) were added to each well of a 96-well plate followed by incubation for an additional 1 h at 37°C. The MTT-reducing activity of the cells was measured by treating them with acidic isopropanol prior to reading at 570 nm using a microplate reader (Tecan Systems Inc., San Jose, CA, USA). The IC₅₀ value was calculated using SigmaPlot 10.0 software (Systat Software Inc., San Jose, CA, USA) with the 4-parameter logistic function standard curve analysis for dose response.

Detection of apoptosis by flow cytometry. The extent of apoptosis was evaluated by flow cytometry using Annexin V-FITC. The cells were grown at a density of 1x10⁶ cells in 6-well plates and treated with various concentrations of CGE [control (DMSO) and 2 x IC₅₀] for 24 h. Following treatment with CGE, the cells were harvested, washed with pre-chilled 1X PBS, and resuspended in 100 µl of binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl₂). Subsequently, 100 ng/ml Annexin V-FITC were added and the mixture was incubated for 10-15 min in the dark at room temperature. PI (20 µg/ml) was added followed by incubation for an additional 15 min in the dark. A total of 400 µl of binding buffer was then added and fluorescence was monitored immediately using an FC500 Flow Cytometer (Beckman Coulter, Fullerton, CA, USA). A total of 10,000 events was collected per sample. The analysis was carried out using CXP analysis software version 2.2 (Beckman Coulter) and the percentage of apoptotic cells was assessed.

Cell cycle distribution analysis. The cells were plated at a density of 1x10⁶ cells/well in a 6-well plate. The cells were treated with various concentrations of CGE [control (DMSO), IC₅₀ and 2 x IC₅₀] for 24 h. After 24 h, the cells were washed twice with PBS. The cells were fixed with 70% ethanol over-
night at 4°C. The fixed cells were washed and resuspended in PBS containing 100 µg/ml RNase A and then incubated for 1 h at 37°C. The cells were stained by the addition of 20 µg/ml PI for 15-20 min at room temperature in the dark. The DNA content of the stained cells was analyzed using an FC500 Flow Cytometer (Beckman Coulter). The data were analyzed using CXP analysis software version 2.2 (Beckman Coulter).

**Determination of ΔΨm by DiOC6(3).** The ΔΨm was determined using the DiOC6(3) dye. The leukemia cells were treated with DMSO (controls) or with the indicated concentrations of CGE for 24 h. Subsequently, the cells were washed in cold PBS, resuspended in PBS supplemented with DiOC6(3) (40 nM), incubated in the dark at 37°C in an incubator with 5% CO2 for 20 min, and then immediately analyzed using an FC500 Flow Cytometer (Beckman Coulter). The data were analyzed using CXP analysis software version 2.2 (Beckman Coulter).

**Caspase activity assay.** The activity of caspase-3/7 was determined using the Caspase-Glo 3/7 Assay kit (Promega Corp., Madison, WI, USA) according to the manufacturer's instructions. The leukemia cells (20,000 cells/well) were seeded in a white 96-well plate and treated with CGE (2 x IC50 concentration) for 1, 3, 6, 12 and 24 h. Caspase-Glo 3/7 reagent (100 µl) was added to each well, and the 96-well plate was incubated on a rotary shaker at room temperature for 10 min, and the luminescence was measured using a microplate reader (Tecan Systems Inc.). The quantification of caspase activity was calculated as the fold increase over the control sample. The caspase activity in the cells treated with CGE was normalized to the caspase activity of the control cell. To evaluate the caspase activity in the presence of various inhibitors, some cells were pre-incubated for 1 h with 50 µM of caspase-3 inhibitor (Z-DEVD-FMK), 50 µM of caspase-8 inhibitor (Z-IEDT-FMK), PI3K inhibitor (LY294002) or ERK inhibitor (U0126).

**Preparation of the mitochondrial and cytosolic fractions.** The leukemia cells (1x10^6 cells) were treated with CGE (2 x IC50 concentration) for 1, 3, 6, 12 and 24 h. The mitochondrial and cytosolic fractions were prepared using the Cytosol/Mitochondria Fractionation kit (Calbiochem, San Diego, CA, USA) according to the manufacturer's instructions. The cytosolic and mitochondrial fractions were stored at -20°C for immunoblot analysis.

**Immunoblot analysis.** The protein concentration of the cytosolic and mitochondrial fractions was determined using the BSA method. An equal quantity of protein (10 µg) was subjected to SDS-PAGE and transferred to PVDF membranes. The successful transfer of the protein was assessed by Ponceau-red staining. The membranes were blocked for 1 h at room temperature in Tris-buffered saline (pH 7.4) containing 0.1% Tween-20 and 5% skim milk. The blocked blots were incubated with primary antibodies overnight at 4°C using antibody dilutions recommended by the manufacturer. Further incubation was performed with HRP-conjugated secondary antibody and the protein expression was detected with the ECL Plus Chemiluminescence kit (Amersham Pharmacia Biotech) according to the manufacturer's instructions.

**Statistical analysis.** Statistical analysis was performed by comparing the mean of the CGE-treated groups with that of the control group using an Student's unpaired t-test (Sigma Plot 10.0). Values of p<0.05, p<0.01, and p<0.001 were considered to indicate statistically significant differences.

**Results**

**Inhibitory effects of CGE on cell growth and the induction of apoptosis in leukemia cells.** MTT assays were conducted to determine the growth inhibitory effects of CGE on leukemia cells. Fig. 1A shows the cell survival rate of the leukemia cells treated with various CGE concentrations as indicated for 24 h. The cell viability was measured by an thiazolyl blue tetrazolium blue (MTT) assay. The data are presented in terms of proportional viability (%) by comparison before and after CGE treatment, with the viability assumed to be 100%. The results are presented as the means ± SD of 3 independent experiments. The significance was determined by the Student's t-test (p<0.05 and ***p<0.001 vs. control). (B) Cells were treated with CGE at the 2 x IC50 concentration for 24 h prior to flow cytometric analysis using Annexin V-FITC/propidium iodide (PI) dual staining. The x-axis indicates the number of Annexin V-FITC-labeled cells. The y-axis indicates the number of PI-labeled cells. (B4) Lower right quadrants and Annexin V-FITC-labeled cells represent the early apoptotic population. (B2) Upper right quadrants represent Annexin V-FITC/PI-dual labeled cells (late apoptotic cells).

- **Figure 1.** Effects of centipedegrass extract (CGE) on cell viability and apoptosis in leukemia cells. (A) Cell viability of Jurkat, CEM-CM3, CCRF-CEM, and MOLT-4 cells treated with various CGE concentrations as indicated for 24 h. The cell viability was measured by an thiazolyl blue tetrazolium blue (MTT) assay. The data are presented in terms of proportional viability (%) by comparison before and after CGE treatment, with the viability assumed to be 100%. The results are presented as the means ± SD of 3 independent experiments. The significance was determined by the Student's t-test (p<0.05 and ***p<0.001 vs. control). (B) Cells were treated with CGE at the 2 x IC50 concentration for 24 h prior to flow cytometric analysis using Annexin V-FITC/propidium iodide (PI) dual staining. The x-axis indicates the number of Annexin V-FITC-labeled cells. The y-axis indicates the number of PI-labeled cells. (B4) Lower right quadrants and Annexin V-FITC-labeled cells represent the early apoptotic population. (B2) Upper right quadrants represent Annexin V-FITC/PI-dual labeled cells (late apoptotic cells).
be 3.91±0.66, 7.35±0.82, 43.16±2 and 51.17±1.57 µg/ml for the Jurkat, CEM-CM3, CCRF-CEM and MOLT-4 cell lines, respectively, using SigmaPlot 10.0 software. These results indicate that CGE exerts a significant cytotoxic effect upon leukemia cells in a dose-dependent manner.

Due to the growth inhibitory effects observed, further experiments to determine whether CGE induces apoptosis in Jurkat cells were warranted (Fig. 1B). After treating the Jurkat cells with the 2 x IC₅₀ concentration of CGE for 24 h, the number of early apoptotic cells increased (60.5%) compared with those for the DMSO control (0.7%). The total percentage of apoptotic cells was directly related to the CGE concentration. This result is consistent with the cytotoxicity assay, and it reveals that CGE induced the apoptosis of Jurkat cells in a dose-dependent manner.

**CGE induces cell cycle arrest in leukemia cells.** As the Jurkat and CEM-CM3 cell lines were highly sensitive to the anti-proliferation effects of CGE, the ability of CGE to interfere with the cell cycle was assessed. The Jurkat and CEM-CM3 cells were incubated with various concentrations (IC₅₀, 2 x IC₅₀) of CGE. Compared with the DMSO-treated controls, treatment with CGE resulted in an appreciable arrest of leukemia cells in the G1 phase of the cell cycle. The G1 phase population of Jurkat cells significantly increased from 47.5% in the control cells to 51.8 and 55.5% at the IC₅₀ and the 2 x IC₅₀ concentrations of CGE, respectively, whereas the G1 phase population in the CEM-CM3 control cells was 32.5% and this increased to 36.8 and 43.1% at the IC₅₀ and the 2 x IC₅₀ concentrations of CGE, respectively, after 24 h of treatment (Fig. 2A). This increase in the G1 cell population was accompanied by a decrease in cell numbers in the S phase and G2/M phase in the leukemia cell lines (Fig. 2B). These results indicate that the cell cycle arrest and the induction of apoptosis may be the key mechanisms behind the antitumor activity of CGE.

**CGE induces mitochondrial dysfunction.** To determine whether the CGE-induced cell apoptosis is mediated through mitochondrial dysfunction, we determined the ∆Ψm with the mitochondria-sensitive dye, DiOC₆(3), by flow cytometry. DiOC₆(3) staining was found to be increased, which indicated that CGE induced a decrease in the ∆Ψm in the leukemia cells. A percentage increase from 8.1 to 34.3% was observed in the number of Jurkat cells with a loss of ∆Ψm, whereas a percentage increase from 11.5 to 25.2% was observed in the number of CEM-CM3 cells with a loss of ∆Ψm (Fig. 3). These findings strongly suggest that the CGE-induced apoptosis in leukemia cells is accompanied by breakdown of the ∆Ψm.
CGE-induced activation of effector caspases and cytochrome c release in leukemia cells. In order to investigate the role of caspases in apoptosis, caspase activity was analyzed after treating the leukemia cells with the 2×IC₅₀ concentration of CGE for 1, 3, 6, 12 and 24 h. We observed that caspase-3/7 activity reached a maximum level (approximately 2-fold over the control) after 12-24 h of incubation (Fig. 4A). In accordance with these results, the addition of cell permeable-specific, irreversible inhibitors of caspase-8 (Z-IETD-FMK) or caspase-3 (Z-DEVD-FMK) enzymes to the leukemia cells revealed that both the Z-IETD-FMK and Z-DEVD-FMK inhibitors completely prevented the CGE-induced activation of caspase-3/7. The CGE-induced apoptosis was inhibited in the presence of Z-VAD-FMK and Z-IETD-FMK, thereby decreasing apoptosis (Fig. 4A and C). Conversely, the combined treatment of CGE with the PI3K inhibitor, LY294002, and the ERK inhibitor, U0126, resulted in enhanced caspase activity. CGE treatment resulted in a significant increase in cleaved effector caspases (caspase-3, -7, and -9) (Fig. 4B).

In addition, we found that treatment with CGE activated caspase-3, -7 and -9 and resulted in the cleavage of the PARP substrate of caspase-3 (Fig. 4D). The effects of CGE treatment on BAX, Bid and cytochrome c in the cytosolic and the mitochondrial fractions isolated from the CGE-treated leukemia cells were evident based on the low amounts of cytochrome c in the cytosol after 2 h; however, the cytochrome c content markedly increased from 3 to 12 h. A time-dependent decrease was observed in the mitochondrial fraction together with a decrease in cytosolic BAX, whereas the cleaved form of Bid and mitochondrial BAX increased, and cleaved Bid decreased in a time-dependent manner (Fig. 4D), which indicates that BAX translocation from the cytosol to the mitochondria induced CGE-mediated apoptosis.

Decreased phosphorylation of PI3K/AKT and MAPK pathway-related proteins. CGE downregulated the phosphorylation of AKT and MAPKs in the leukemia cells. We examined CGE-induced cell death by measuring the activation of apoptotic proteins in leukemia cells. The cells were treated with CGE (2×IC₅₀ concentration) for 0, 1, 3, 6, 12 and 24 h. CGE induced a decrease in the levels of p-PI3K, p-AKT (Ser 473), p-AKT (Thr 308), p-BAD, p-ERK and p-JNK, but the p-p38 protein levels were not altered (Fig. 5).

Discussion

The compositional analysis of CGE has demonstrated that it is composed of various C-glycosidic flavonoids, such as maysin and its derivatives, including luteolin, orientin, isoorientin, rhamnolysyl isoorientin, derhamnosly maysin and luteolin-6-C-boivinopyranose (17). CGE has been reported to exhibit several biological activities, such as pancreatic lipase inhibitory activity, antioxidant activity (4) and insecticidal activity (5). The presence of C-glycosidic flavonoids, such as maysin and its derivatives, in CGE may attribute to the anticancer properties of CGE. Our results demonstrated that CGE inhibited cell proliferation in 4 human leukemia cell lines in a dose-dependent manner. The biochemical mechanisms through which CGE exerts its effects remain unclear, and the present study aimed to identify the molecular signaling pathways involved in the induction of apoptosis by CGE. Our results clearly demonstrated that CGE inhibited the growth of leukemia cells by inducing apoptotic cell death as determined by Annexin V-FITC analysis (Fig. 1). Generally, the early apoptotic translocation of the phospholipid PS from the inner to outer leaflet of the plasma membrane occurs due to the loss of membrane asymmetry, which can be detected by the binding of Annexin V-FITC to PS (22,23).

Cell cycle control has been proven to be a major event in cellular division. The disruption of the normal cell cycle plays a vital role in the development of cancer. A large number of anticancer natural compounds have been shown to induce cell death and apoptosis in close association with cell cycle arrest at the G1 phase (9,24-26). In this study, Jurkat and CEM-CM3 cells treated with CGE showed a significant accumulation of cells in the G1 phase; there was a concurrent reduction of
the cell population in S and G2/M phase in a dose-dependent manner (Fig. 2), which suggests that the anti-proliferative effects of CGE are mainly due to the induction of apoptosis.

There are two types of apoptotic cysteine-dependent aspartate-directed caspases: initiator and effector (executioner) caspases. Initiator caspases (e.g., caspase-8 and -9) cleave and activate effector caspases (e.g., caspase-3, -6 and -7), which in turn triggers the apoptotic process (27). Caspase-3 has been shown to inactivate or cleave nuclear proteins, such as PARP, which plays an important role in DNA repair (28). The initiation of this cascade reaction is regulated by caspase inhibitors, which can originate from a number of natural compounds (29,30). In this study, caspase activation was examined by treating the leukemia cells with CGE. Caspase-3/7 activity increased in a time-dependent manner to approximately 2-fold over the controls after 12-24 h (Fig. 4A). Blocking caspase activation using Z-IETD-FMK and Z-DEVD-FMK (***p<0.001). (B) Caspase-3/7 activity in the presence or absence of the specific phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, and the ERK inhibitor, U0126 (***p<0.001). (C) Apoptotic cell death measured by Annexin V-FITC and propidium iodide (PI) by flow cytometry. Cells were treated with CGE (2 x IC₅₀) for 24 h in the presence or absence of a general caspase inhibitor. (D) Whole cell lysates were prepared after the cells were incubated with CGE for the indicated periods of time. Lysates were used for the detection of caspase-3, -7, -9, and poly(ADP-ribose) polymerase (PARP) in CGE-treated Jurkat and CEM-CM3 cells. GAPDH was used as an internal control. (E) The cytosolic and mitochondrial fractions were prepared as described in the Materials and methods. Cell lysates (10 µg) were subjected to 12% SDS-PAGE and immunoblotted with the Bid, BAX, and cytochrome c antibodies. A GAPDH antibody (for the cytosolic fraction) and an HSP-60 antibody (for the mitochondrial fraction) were used as the loading controls.

Figure 4. Jurkat and CEM-CM3 cells treated with the 2 x IC₅₀ concentration of centipedegrass extract (CGE), for the indicated periods of time. (A) Time-dependent detection of caspase-3/7 activity in the presence or absence of specific caspase inhibitors, such as Z-IETD-FMK and Z-DEVD-FMK (***p<0.001).
PI3K inhibitor, LY294002, and the ERK inhibitor, U0126, enhanced the CGE-induced apoptosis (Fig. 4B) and further activated the effector caspases (caspase-3, -7, and -9) with the concomitant induction of apoptosis (Fig. 4C).

Apoptotic signaling occurs through the mitochondria and involves the cellular redistribution of BAX and cytochrome c followed by the activation of multiple caspases, which manifest the apoptotic phenotype. During this process, decreased cytosolic levels of BAX, increased cytosolic levels of cytochrome c and cleaved Bid are observed (31,32). In this study, to better understand the cellular redistribution of proteins in CGE-induced apoptosis, we examined changes in the levels of proteins by western blot analysis. The levels of BAX decreased gradually, whereas the levels of cytochrome c and cleaved Bid increased in the cytosolic fraction (Fig. 4D).

To the best of our knowledge, this study is the first to demonstrate the anticancer effects of C-glycosidic flavonoids, such as
maysin and its derivatives, in CGE, which inhibit the growth of leukemia cells. Our results are summarized in Fig. 6. The selective inhibition of cancer cell growth, apoptosis induction via the significant G1 cell cycle arrest and BAX translocation from the cytosol to the mitochondria induced the disruption of the ΔΨm, thereby increasing the caspase-3/7 activity and activation of effector caspase-3, -7 and -9. In addition, CGE inhibited PI3K activity by reducing p-AKT, p-BAD, and Bcl-2 levels and inhibited MAPKs, including p-ERK and p-JNK. Taken together, CGE may prove to be a potential chemopreventive agent in the treatment of ALL.

Acknowledgements

This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (No. 2012M2A2A6036022).

References